Some reports describe high Mesothelin expression to be associated with a more aggressive behavior of the tumor and worse prognosis in breast, lung and gastric cancer [9–11] while others found no impact of Mesothelin overexpression on prognosis in gastric and breast cancer, or even an improved prognosis, respectively [12, 13]. This evidence concerns the gene MSLN and neoplasm.